References
- Biotechnology in a Global Economy. National Technical Information Service, Springfield, VA October, 1991, U.S. Congress, Office of Technology Assessment, OTA-BA-494
- New Developments in Biotechnology: U.S. Investment in Biotechnology. National Technical Information Service, Springfield, VA July, 1988, U.S. Congress, Office of Technology Assessment, OTA-BA-360
- Jadlow J. M. A summary and critique of economic studies of the ethical drug industry: 1962–1968. Issues in Pharmaceutical Economics, R. I. Chien. Lexington Books, Lexington, MA 1979
- 1991 U.S. Industrial Outlook. U.S. Government Printing Office, Washington, DC January, 1991, U.S. Department of Commerce, International Trade Administration
- Hearings on the Advertising, Marketing, and Promotional Practices of the Pharmaceutical Industry. December, 1990, U.S. Congress, Senate Committee on Labor and Human Resources, Serial No. 101–1217
- Biotech 91: A Changing Environment. Ernst & Young, San Francisco 1990
- Gupta U. U.S. biotechnology industry's growth is hindered by bottlenecks, study finds. Wall Street J Oct 29, 1991; B8
- , U.S. Congress, Office of Technology Assessment: Biotechnology in a Global Economy: Options for U.S. Strategy, transcript of a workshop held May 2, 1989, Washington, DC.
- Chase M. Genentech plans to sell 60 percent stake to Roche Holdings for $2.1 billion. Wall Street J Feb 5, 1990
- Gershon D. Cetus and Chiron merge. Nature 1991; 352(6334)364
- Thayer A. Genetics Institute: Firm sells 60% share for $666 million. Chem Eng News 1991; 69(39)6
- Werner W. M. Biobusiness in the pharmaceutical industry. Arzneim-Forsch 1987; 37(9)1086–1093, Part II
- Wardell W. M. The history of drug discovery, development, and regulation. Issues in Pharmaceutical Economics, R. I. Chien. Lexington Books, Lexington, MA 1979
- Netzer W. J. Emerging tools for discovering drugs. Bio/Technology 1990; 8(7)618–622
- Ganellin C. R. FRS, Discovering new medicines. Chem Indust 1989; 1: 9–15
- Savitz E. J. The war against cancer, it still rages after 20 years and $20 billion. Barren's 1990; 70(9)6–7; 15–16; 25–27
- , Pharmaceutical Manufacturers Association, Washington, DC: Biotechnology Medicines in Development, 1990 Annual Survey.
- , Pharmaceutical Manufacturers Association, Washington, DC: Biotechnology Medicines in Development, 1991 Annual Survey.
- Mossinghoff G. J. Jan 17, 1991, President: Pharmaceutical Manufacturer's Association, statement at hearings before the International Trade Commission
- Baum R. Biotech industry moving pharmaceutical products to market. Chem Eng News 1987; 65(29)11–14
- Cetus loss widened in fiscal 4th quarter; drug costs are cited. Wall Street. J. Aug 1990; 8: B4
- Mansfield E. Patents and innovation: An empirical study. Management Sci 1986; 32(2)173–181
- Cocks D. L. Economic and competitive aspects of the pharmaceutical industry. Principles of Pharmaceutical Marketing, 3rd ed, M. C. Smith. Lea & Febiger, Philadelphia 1983
- Grabowski H., Vernon J. Longer patents for lower imitation barriers: The 1984 drug act. Am Econ Rev 1986; 76(2)195–198
- Fujii M. Government's support for pharmaceutical industry. Business Jpn 1988; 33(7)80–83
- U.S. Congress, General Accounting Office. Biotechnology: Backlog of Patent Applications. U.S. Government Printing Office, Washington, DC 1989